Advances in Heart Failure: A Year of Discovery – SGLT2 Inhibitor Trials and Implications for Practice

PART 1: SGLT2 Inhibition in Changing the HF Paradigm

Learning objectives

  • Evaluate emerging data on the treatment of heart failure with SGLT2 inhibitors in patients with or without T2DM
  • Interpret the new data on the treatment of heart failure with SGLT2 inhibitors in patients with or without T2DM in relationship to the existing data.
  • Understand the implementation of the emerging data on the treatment of heart failure with SGLT2 inhibitors in patients with or without T2DM for clinical practice.

 


Programme Outline
  • PART 1: SGLT2 Inhibition in Changing the HF ParadigmAndrew JS CoatsPiotr PonikowskiStefan Anker
  • PART 2: Latest Evidence for SGLT2 in HF – 2020 So FarAndrew JS CoatsPiotr PonikowskiStefan Anker
  • PART 3: Latest Evidence and Key Upcoming HFrEF Data 2020Andrew JS CoatsPiotr PonikowskiStefan Anker
  • PART 4: The Future is Near – Unmet Needs in HFpEFCarolyn Lam
Supported by an unrestricted educational service from Boehringer Ingelheim

PART 2: Latest Evidence for SGLT2 in HF – 2020 So Far